Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW to Track Prescription Shifts under OTC-Like Drug Charge
Japanese Health Minister Kenichiro Ueno said on September 15 that the government plans to monitor prescription shifts following the rollout of its additional charge for “OTC-like” prescription medicines. Speaking at a regular press conference, Ueno said the Ministry of Health,…
To read the full story
Related Article
- No Financial Aid Planned for OTC-Like Drug Charge System Changes: Ueno
October 5, 2026
- Japan Finalizes Framework for OTC-Like Drug Charge Ahead of March Rollout
September 17, 2026
- Atopic Dermatitis Proactive Therapy to Be Exempt from OTC-Like Drug Charge
September 14, 2026
- OTC-Like Drug Charge Gets Prescription Field; No Double Charge with LLP Rule
September 10, 2026
- Minister Defends Scope of Low-Income Exemption for OTC-Like Drug Charge
September 7, 2026
- Japan to Revisit Handling of Steroid Creams under OTC-Like Drug Charge
September 4, 2026
- MHLW Eyes Tax Exemption for OTC-Like Drug Charges
September 1, 2026
- Patient Group Flags Risks of Inconsistent Decisions on OTC-Like Drug Charges
August 28, 2026
- MHLW Maps Out Workflow for OTC-Like Drug Charges
August 27, 2026
- MHLW Panel Finalizes Exemptions for OTC-Like Drug Charges
August 17, 2026
REGULATORY
- Takaichi Puts Health Security on Crisis Management Investment Agenda
October 6, 2026
- Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
- RMPs to Become Statutory Requirement under PMD Act in May 2027
October 5, 2026
- Japan Panel Calls for Better Infrastructure to Expand RLT Access
October 5, 2026
- Drug Discovery Fund Cleared to Provide Funding to Startups
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…